In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Endo, Vernalis Finds a Believer in Frova

Executive Summary

Endo Pharmaceuticals licenses US rights to Vernalis' migraine drug Frova. The specialty pharma firm feels it can differentiate Frova from significant competition in the triptan market through its specialist-focused marketing approach and by extending Frova's label to include prevention of menstrually associated migraine.
Advertisement

Related Content

The Shake Up At Endo Pharma
The Shake Up At Endo Pharma
European Biotech Is Specialty Pharma
European Biotech Is Specialty Pharma
Endo: Accessing Primary Care through Specialist Marketing
Endo: Accessing Primary Care through Specialist Marketing
Europe's Flavors of Sustainable BioPharma
Europe's Flavors of Sustainable BioPharma
Vernalis Gives Partnering a Second Chance
Vernalis Gives Partnering a Second Chance

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel